002020 京新药业
已收盘 09-14 15:00:00
资讯
新帖
简况
9月7日京新药业（002020）龙虎榜数据：机构净卖出1.1亿元，北向资金净买入7.87万元
证券之星 · 09-07
9月7日京新药业（002020）龙虎榜数据：机构净卖出1.1亿元，北向资金净买入7.87万元
京新药业跌6.62% 西部证券今日刚维持买入评级就跌
中金财经 · 09-07
京新药业跌6.62% 西部证券今日刚维持买入评级就跌
京新药业：地达西尼的销量2026年二季度环比一季度有增长
证券之星 · 09-04
京新药业：地达西尼的销量2026年二季度环比一季度有增长
京新药业：公司基于管线布局和投入产出的情况综合考虑，目前该项目处于暂停状态
证券之星 · 09-04
京新药业：公司基于管线布局和投入产出的情况综合考虑，目前该项目处于暂停状态
京新药业（002020）披露股份回购进展公告，9月1日股价上涨1.09%
证券之星 · 09-01
京新药业（002020）披露股份回购进展公告，9月1日股价上涨1.09%
西南证券：给予京新药业买入评级
证券之星 · 09-01
西南证券：给予京新药业买入评级
【机构调研记录】红土创新基金调研京新药业
证券之星 · 08-28
【机构调研记录】红土创新基金调研京新药业
【机构调研记录】浙商基金调研水星家纺、京新药业
证券之星 · 08-28
【机构调研记录】浙商基金调研水星家纺、京新药业
京新药业（002020）2026年中报简析：净利润同比下降9.35%
证券之星 · 08-28
京新药业（002020）2026年中报简析：净利润同比下降9.35%
股市必读：京新药业中报 - 第二季度单季净利润同比下降16.99%
证券之星 · 08-28
股市必读：京新药业中报 - 第二季度单季净利润同比下降16.99%
京新药业：兴业证券、华西证券等多家机构于8月27日调研我司
证券之星 · 08-27
京新药业：兴业证券、华西证券等多家机构于8月27日调研我司
京新药业(002020)6月30日股东户数3.29万户，较上期增加3.48%
证券之星 · 08-27
京新药业(002020)6月30日股东户数3.29万户，较上期增加3.48%
京新药业：盐酸卡立哌嗪已经获批，公司已做好生产计划，会尽快安排上市销售
证券之星 · 08-27
京新药业：盐酸卡立哌嗪已经获批，公司已做好生产计划，会尽快安排上市销售
京新药业：JX11502目前是暂停的状态
证券之星 · 08-27
京新药业：JX11502目前是暂停的状态
京新药业2026年半年报：器械业务增长，营收利润小幅下滑
蓝鲸财经 · 08-27
京新药业2026年半年报：器械业务增长，营收利润小幅下滑
图解京新药业中报：第二季度单季净利润同比下降16.99%
证券之星 · 08-27
图解京新药业中报：第二季度单季净利润同比下降16.99%
公司问答丨京新药业：公司盐酸卡立哌嗪已经获批 地达西尼的销售也在积极推进中
格隆汇 · 08-24
公司问答丨京新药业：公司盐酸卡立哌嗪已经获批 地达西尼的销售也在积极推进中
公司问答丨京新药业：公司在正常推进H股上市事项
格隆汇 · 08-24
公司问答丨京新药业：公司在正常推进H股上市事项
京新药业：公司盐酸卡立哌嗪已经获批
证券之星 · 08-24
京新药业：公司盐酸卡立哌嗪已经获批
新股消息 | 京新药业(002020.SZ)港股IPO招股书失效
智通财经 · 08-11
新股消息 | 京新药业(002020.SZ)港股IPO招股书失效
加载更多
公司概况
公司名称：
浙江京新药业股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-15
主营业务：
浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司为国家重点高新技术企业。
发行价格：
10.05
{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":11.51,"timestamp":1789369380000,"preClose":11.3,"halted":0,"volume":10004967,"delay":0,"changeRate":0.0186,"floatShares":724000000,"shares":861000000,"eps":0.8383,"marketStatus":"已收盘","change":0.21,"latestTime":"09-14 15:00:00","open":11.3,"high":11.55,"low":11.25,"amount":114000000,"amplitude":0.0265,"askPrice":11.52,"askSize":108,"bidPrice":11.51,"bidSize":9,"shortable":0,"etf":0,"ttmEps":0.8383,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"adjPreClose":11.3,"symbolType":"stock","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":12.43,"lowLimit":10.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":1.62,"roa":"--","peRate":13.730168,"roe":"5.78%","epsLYR":0.92,"committee":-0.266028,"marketValue":9910000000,"turnoverRate":0.0138,"status":0,"floatMarketCap":8333000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2665431416","title":"9月7日京新药业（002020）龙虎榜数据：机构净卖出1.1亿元，北向资金净买入7.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665431416","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665431416?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:52","pubTimestamp":1788774779,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年9月7日公布的交易公开信息显示，京新药业因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年9月7日收盘，京新药业报收于11.84元，下跌6.62%，换手率5.62%，成交量40.7万手，成交额4.84亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出1.1亿元，北向资金合计净买入7.87万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390288","title":"京新药业跌6.62% 西部证券今日刚维持买入评级就跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390288","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665390288?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:15","pubTimestamp":1788768907,"startTime":"0","endTime":"0","summary":"中国经济网北京9月7日讯 今日，京新药业(002020.SZ)收报11.84元，跌幅6.62%。\r\n\r\n 西部证券股份有限公司研究员李梦园、邓琳茜于今日发布研报《京新药业(002020)2026年中报点评：地达西尼加速放量 仿创结合、产品矩阵持续丰富》称，基于公司地达西尼加速放量、创新管线稳步推进，维持“买入”评级。\r\n\r\n (责任编辑：魏京婷)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260907/32362070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002020","002673"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664342336","title":"京新药业：地达西尼的销量2026年二季度环比一季度有增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2664342336","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664342336?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:28","pubTimestamp":1788517699,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在5月分的时候说过地达西尼一季度销量同比环比上涨，也就是说一季度最少卖了8500万以上，上半年的销量1.53亿，请问二季度销量环比下跌的原因是什么？京新药业回复：您好！地达西尼的销量2026年二季度环比一季度有增长，2026年上半年累计销售额1.53亿元。公司会努力推进地达西尼的销售。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400035208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664133630","title":"京新药业：公司基于管线布局和投入产出的情况综合考虑，目前该项目处于暂停状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2664133630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664133630?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:28","pubTimestamp":1788517699,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问11502项目暂停的原因是什么？是数据不理想还是其他？京新药业回复：您好!公司基于管线布局和投入产出的情况综合考虑，目前该项目处于暂停状态。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400035209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664508008","title":"京新药业（002020）披露股份回购进展公告，9月1日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664508008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664508008?lang=zh_cn&edition=full","pubTime":"2026-09-01 23:05","pubTimestamp":1788275119,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，京新药业报收于12.97元，较前一交易日上涨1.09%，最新总市值为111.68亿元。该股当日开盘12.81元，最高13.0元，最低12.79元，成交额达9270.59万元，换手率为0.99%。近日，京新药业发布《关于股份回购进展公告》。公告显示，公司于2026年7月2日召开第九届董事会第五次会议，7月20日召开2026年第二次临时股东大会，审议通过回购股份用于注销并减少注册资本的议案。回购符合相关法规及既定方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664583108","title":"西南证券：给予京新药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664583108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664583108?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:08","pubTimestamp":1788257316,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳近期对京新药业进行研究并发布了研究报告《2026半年报点评：业绩承压，创新转型持续推进》，给予京新药业买入评级。公司创新药物加速放量，创新转型持续推进，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为19.11。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100032387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034195","title":"【机构调研记录】红土创新基金调研京新药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034195?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:16","pubTimestamp":1787876177,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月27日披露的机构调研信息，红土创新基金近期对1家上市公司进行了调研，相关名单如下：1）京新药业 调研纪要：2026年上半年，地达西尼销售额达1.53亿元，公司正加强自营团队建设以推动销售。旗下最近一年表现最佳的公募基金产品为红土创新新兴产业混合A，最新单位净值为4.52，近一年增长118.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800015303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662341580","title":"【机构调研记录】浙商基金调研水星家纺、京新药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2662341580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662341580?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:16","pubTimestamp":1787876172,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月27日披露的机构调研信息，浙商基金近期对2家上市公司进行了调研，相关名单如下：1）水星家纺 调研纪要：雪糕被6.0和人体工学枕4.0顺利上市，巩固爆款基本盘并体现品类溢出效应。2）京新药业 调研纪要：2026年上半年，地达西尼销售额达1.53亿元，公司正加强自营团队建设以推动销售。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800015297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0247","BK0239","603365","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662527039","title":"京新药业（002020）2026年中报简析：净利润同比下降9.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662527039","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662527039?lang=zh_cn&edition=full","pubTime":"2026-08-28 06:25","pubTimestamp":1787869536,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期京新药业发布2026年中报。根据财报显示，京新药业净利润同比下降9.35%。截至本报告期末，公司营业总收入19.87亿元，同比下降1.46%，归母净利润3.52亿元，同比下降9.35%。持有京新药业最多的基金为兴业医疗保健混合A，目前规模为1.9亿元，最新净值0.7704，较上一交易日上涨1.01%，近一年下跌12.32%。2026 年上半年，地达西尼延续增长态势，销售额达 1.53 亿元。本文数据来源于京新药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800011270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662353200","title":"股市必读：京新药业中报 - 第二季度单季净利润同比下降16.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662353200","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662353200?lang=zh_cn&edition=full","pubTime":"2026-08-28 05:00","pubTimestamp":1787864441,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，京新药业报收于13.25元，上涨1.53%，换手率2.22%，成交量16.09万手，成交额2.09亿元。业绩披露要点：2026年中报显示归母净利润3.52亿元，同比下降9.35%。机构调研要点：地达西尼2026年上半年销售额达1.53亿元，延续增长态势。第二季度单季度主营收入10.64亿元，同比上升0.35%；归母净利润1.86亿元，同比下降16.99%；扣非净利润1.86亿元，同比下降12.74%；负债率24.07%，毛利率50.5%，投资收益1278.43万元，财务费用-47.14万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662000607","title":"京新药业：兴业证券、华西证券等多家机构于8月27日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2662000607","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662000607?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:02","pubTimestamp":1787835760,"startTime":"0","endTime":"0","summary":"2026 年上半年，地达西尼延续增长态势，销售额达 1.53 亿元。后续，公司会积极加强自营团队补充，持续推进地达西尼销售进展，为公司营收增长奠定基础。京新药业主营业务：化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家；过去90天内机构目标均价为19.74。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002926","BK0028","BK0183","BK0012","BK0239","BK0188","601377","BK0276","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703526","title":"京新药业(002020)6月30日股东户数3.29万户，较上期增加3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703526","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662703526?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:06","pubTimestamp":1787825183,"startTime":"0","endTime":"0","summary":"证券之星消息，近日京新药业披露，截至2026年6月30日公司股东户数为3.29万户，较3月31日增加1108.0户，增幅为3.48%。在化学制药行业个股中，京新药业股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，京新药业区间跌幅为18.41%，在此期间股东户数增加1108.0户，增幅为3.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662777080","title":"京新药业：盐酸卡立哌嗪已经获批，公司已做好生产计划，会尽快安排上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2662777080","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662777080?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:31","pubTimestamp":1787823086,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司准创新药盐酸卡立哌嗪为什么已获批两个月却还没推到市场端，具体什么原因？难道公司就这样的效率？京新药业回复：您好！盐酸卡立哌嗪已经获批，公司已做好生产计划，会尽快安排上市销售。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700041123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662770877","title":"京新药业：JX11502目前是暂停的状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2662770877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662770877?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:31","pubTimestamp":1787823086,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公创新药11502目前进展三期快完成了吗？作为领雁项目它的优势是什么？京新药业回复：您好！JX11502目前是暂停的状态。具体进展敬请关注相关公告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700041122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662229047","title":"京新药业2026年半年报：器械业务增长，营收利润小幅下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662229047","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662229047?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:22","pubTimestamp":1787800936,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月27日讯，8月26日，京新药业 公布2026年中报，公司依托精神神经、心脑血管及医疗器械三大核心板块协同发力，受益于创新药放量及精益生产降本增效，报告期业绩整体保持稳健，但受部分业务承压影响营收与利润小幅下滑；同时，盐酸卡立哌嗪胶囊获国内首仿批准，创新转型成效持续显现。财报数据显示，报告期公司实现营业收入19.87亿元，同比下降1.46%；归母净利润3.52亿元，同比下降9.35%；扣非净利润3.42亿元，同比下降5.15%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787795479626076438","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662070746","title":"图解京新药业中报：第二季度单季净利润同比下降16.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662070746","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662070746?lang=zh_cn&edition=full","pubTime":"2026-08-27 02:04","pubTimestamp":1787767487,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业2026年中报显示，上半年度公司主营收入19.87亿元，同比下降1.46%；归母净利润3.52亿元，同比下降9.35%；扣非净利润3.42亿元，同比下降5.15%；其中2026年第二季度，公司单季度主营收入10.64亿元，同比上升0.35%；单季度归母净利润1.86亿元，同比下降16.99%；单季度扣非净利润1.86亿元，同比下降12.74%；负债率24.07%，投资收益1278.43万元，财务费用-47.14万元，毛利率50.5%。财报数据概要请见下图:本文数据来源于京新药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700006117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661123229","title":"公司问答丨京新药业：公司盐酸卡立哌嗪已经获批 地达西尼的销售也在积极推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2661123229","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661123229?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:58","pubTimestamp":1787558284,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229130","title":"公司问答丨京新药业：公司在正常推进H股上市事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229130","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661229130?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:57","pubTimestamp":1787558231,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241782","title":"京新药业：公司盐酸卡立哌嗪已经获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241782","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661241782?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:45","pubTimestamp":1787532311,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)08月24日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司准创新药盐酸卡立哌嗪开始上市销售了吗？如果没有预计什么时间开始销售。零外公司地达西尼销量是否继续同步增长？京新药业回复：您好！公司盐酸卡立哌嗪已经获批，公司会尽快做好生产计划，安排上市销售。地达西尼的销售也在积极推进中。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400002690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658917957","title":"新股消息 | 京新药业(002020.SZ)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917957","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658917957?lang=zh_cn&edition=full","pubTime":"2026-08-11 06:16","pubTimestamp":1786400190,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，浙江京新药业股份有限公司(简称：京新药业，002020.SZ)于2026年2月11日所递交的港股招股书满6个月，于2026年8月11日失效，递表时中信证券为其独家保荐人。据此前招股书披露，京新药业是一家以创新为驱动力的制药集团，策略重点专注于两大核心疾病领域：中枢神经系统疾病;及心血管及脑血管疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","FRHC","002020","BK4127","KCAI","VXUS","BK0239","BK4588","KCE","REDS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789431869031,"stockEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.1808},{"period":"3month","weight":-0.0558},{"period":"6month","weight":-0.2751},{"period":"1year","weight":-0.3986},{"period":"ytd","weight":-0.3771}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"181849人(较上一季度增加35981.15%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":" 浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司为国家重点高新技术企业。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}